Variety of qualified sufferers: CDEC talked about the uncertainty in the quantity of sufferers with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who will be categorised as acquiring gentle or moderate disease may have a intense bleeding